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 Introductions: Dasatinib is indicated as a first line, second line and third 
line tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML). In 
our center it is used as a second line or third line therapy in BCR-ABL 
gene positive CML. 
 
Methods: It is a retrospective observational therapy done from June 
2015 to May 2018.   The purpose of the study is to see the response rates 
using the second line and third line dasatinib after failing or not 
tolerating imatinib alone or following a sequential therapy with imatinib 
and nilotinib. 
 
Results: A total of 31 (male 56.3%) patients were included in our study. 
In eighteen patients it was used as a second line TKI and in 13 a third line 
TKI. Complete Hematologic Response (CHR) was achieved in 93.55%. Best 
optimal responses were 46.66% and 61.53% in second and third line 
dasatinib respectively. Major Molecular Response (MMR) was achieved 
in 35.71% (26.66% and 46.14% in second line and third line dasatinib 
respectively). For both the groups, the overall survival was 92% and 94 % 
at 20 months and the event free survival was 70% at 10 months. 
  
 
Conclusions:  Dasatinib is effective in achieving MMR and inducing 
survival benefit in the patients who failed imatinib alone and imatinib 
and nilotinib. 
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Resistance or intolerance to imatinib-treated 
chronic myeloid leukemia (CML) patients are 
seen in 33% and yet, 33% of the patients 
never achieve complete cytogenetic response 
(CCyR).1,2 Clinical resistance to imatinib is 
divided into either primary if the patient 
showed lack of efficacy from the initiation of 
the therapy, or secondary if resistance 
develops after initial response,1,3 
characterized by loss of Major Cytogenetic 
Response (MCyR).6 Resistance is further 
classified as hematologic (absence of 
normalization of blood counts), cytogenetic 
(persistence of Ph+ cells) and molecular 
(persistence of BCR-ABL transcripts by the 
Reverse Polymerase Chain Reaction ‘RTPCR’6 
as per the National Comprehensive Cancer 
Network (NCCN)  guidelines 2018.1,6 
 
Resistance is considered if at three months, 
the BCR-ABL transcripts is >10% by 
Quantitative Polymerase Chain Reaction 
(QPCR) or, in absence of Partial Cytogenetic 
Response (PCyR), at six months. If the above 
response persists or there is a mutation that 
has known resistance to imatinib and at 12 
months or later if the BCR-ABL transcript is 
>1% or presence of mutation.1 
 
In this study, we have tried to report the 
response rates and the results using second 
generation Tyrosine Kinase Inhibitor (TKI) 
dasatinib as a second and third generation 
TKI, after failure or intolerance to imatinib 
alone and response rates in these patients 
who had failed or developed intolerance to 
the sequential use of imatinib and nilotinib 
following imatinib resistance. 
 
 
Table 1. Definitions of the Accelerated Phase and Blast Phase as defined by the WHO guideline and 
definitions of the various responses3,4,5,6 
 
Accelerated Phase   
Peripheral Blood Blast >/=10% and =/< 19%, 
Peripheral Blood Basophils >20% 
Platelet Count Unrelated to Therapy </=100*109/L 
Thrombocytosis >1000*109 
Increasing Spleen Size   
Cytogenetic Evidence of Clonal Evolution  
Blast Phase  
Peripheral White Blood Cells or  
of Nucleated Bone Marrow Cells 
>/=20% blasts 
Complete Hematologic Response  
Complete normalization of peripheral blood 
counts with absence of immature cells such as 
myelocytes, promyelocytes, or blasts in the 
peripheral blood 
 
Leukocyte Count <10*109/L 
Platelet Count <450*109/L 
Cytogenetic Response  
Complete Cytogenetic Response (CCyR) no Ph positive metaphases 
Partial Cytogenetic Response (PCyR) 1-35% Ph positive metaphases 
Major Cytogenetis Response (MCyR) 0-35% Ph positive metaphases 
Minor Cytogenetic Response (mCyR) >35% Ph positive metaphases 
Molecular Response  
Early Molecular Response (EMR) BCR-ABL (IS) =/< 1-10% at 3 and 6 months 
Major Molecular Response (MMR) BCR-ABL (IS) =/< 0.1% or =/> 3 log reduction in BCR-
ABL messenger ribonucleic acid (mRNA) from the 
standardized baseline 
Complete Molecular Response or deep 
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This was a cross-sectional study done at Patan 
Hospital in Nepal, on the patients who had 
been receiving dasatinib after developing 
resistance or showed intolerance to the first 
line TKI - imatinib and after failure or 
intolerance to second line TKI - nilotinib. All 
the charts of the patients who had received 
dasatinib were studied. The patients included 
were: BCR-ABL gene positive Chronic Myeloid 
Leukemia; patient with documented results 
complete blood count, cytogenetic tests, 
molecular tests; documentation of failure or 
intolerance to imatinib only and nilotinib. 
Patients who do not have the documented 
reports of the above tests were excluded. 
Data were collected from June 2015 to May 
2018.  
 
Baseline characteristics like name, age, sex, 
address, whether the patient received 
imatinib alone or was sequentially treated 
with imatinib and nilotinib and the median 
time taken were calculated. The phase 
(chronic, accelerated and blast phases, table 
1) at which the various TKIs used were also 
noted. The mutational analyses were done by 
IRMA (Imatinib Resistance Mutation Analysis) 
and their results were also recorded. The best 
optimal response achieved (hematological, 
cytogenic and molecular, table 1) with 
imatinib and nilotinib were recorded and the 
reasons for stopping them and the phase at 
stopping them were also noted. Similarly, the 
best response achieved with the use of 
dasatinib and the final outcomes were 
documented. Optimal response was said to be 
present if there was at least early molecular 
response (EMR) at 3 to 6 months, at least a 
complete cytogenetic response at 6 months, 
and at least a major molecular response 
(MMR) at 12 months and thereafter. The 
response rates lying between the optimal and 
resistance are termed as warning responses. 
The response rates were evaluated as per the 
NCCN 2018 guidelines1 for the management 
of Chronic Myeloid leukaemia. 
 
The patient outcome was studied including 
the percentage of hematologic responses, 
cytogenetic responses and the molecular 
responses, mutations and outcomes; overall 
survival and, event free survival were 
calculated by using SPSS 20 software. The 
events were defined as the failure response, 





A total of 32 patients were started on 
dasatinib as a second line or the third line TKI. 
One patient was excluded from the study as 
he was newly started with dasatinib and the 
reports were not available. So, the total of 31 
patients were included with males 18 
(58.06%). The median age of the patients was 
45 years (range 15-80). One patient received 
hydroxyurea and another received 
hydroxyurea and interferon before being 
enrolled in our center. 
 
Imatinib as a first line TKI: All of the 31 
patients received imatinib as a first line of 
treatment, median time on imatinib was 47.5 
months (range 1-159). At baseline, 30 
(96.77%) patients were in the chronic phase 
and one (3.23%) in accelerate phase. The best 
responses achieved with imatinib were 
optimal response 12 (46.15%), warning and 
fail 14 (53.85%) data was not available in rest 
5 patients. Four (12.9%) patients were taken 
off imatinib due to intolerance out of which 
three (75%) had optimal response as a best 
response and the response status of one 
patient was not known. Two out of those 
three patients later developed secondary 
resistance to imatinib. In the remaining 27 
(87.09%) patients, imatinib was discontinued 
due to resistance.  
 
Out of 29 patients whose latest response was 
failure 13 (41.93%) patients developed 
hematologic failure, two (6.45%) developed 
cytogenetic failure, 14 (45.16%) patients had a 
molecular failure, one (3.22%) patient had 
optimal response and data of one patient was 
not available but had maintained the CHR, 
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Mutational was performed in 27 (87.09%) 
patients. Mutation was seen in 15 (55.55%) 
patients when resistance was documented 
and it was not seen in 12 (44.44%). The 
presence of mutations associated with the 
strong resistance to imatinib like Y253H, 
G250E, and L248V were seen in 5 (33.33%) 
patients out of which four patients had 
primary resistance and one had secondary 
resistance (G250E). Mutations with 
intermediate resistance to imatinib M244V, 
H396R, F359V/C, L387M and M351T were 
seen in 9 (60%) patients. Out of which five 
(M244V-1, F359V-2, F359C-1 M351T-1) had a 
primary resistance two (L387M-1, F359V-1) 
had a secondary resistance to imatinib and in 
two (H396R) categorization was not done 
because of the missing data. Presence of 
E275K and A269S mutation conferred a 
primary and secondary resistance to imatinib 
respectively.  
 
Mutations sensitive to dasatinib F359V, 
L387M, G250E, Y253H, M244V, H396R, 
M351T and intermediate sensitivity mutation 
E255V and F317L were found in our patients 




Table 2. Patients characteristics before starting imatinib, dasatinib as a 2nd line TKI, nilotinib, dasatinib as a 
3rd line TKI, the best responses achieved, results as per the latest reports and the reason for discontinuing it 
 
TKI and Number of 
Patients 






Stage at start of TKI     
     Chronic Phase (CP) 30 (96.77%) 3 (16.66%) 5 (38.46%) 5 (38.46%) 
     Accelerated Phase (AP) 1 (3.22%) 1 (5.55%) 3 (23.07%) 4 (30.76%) 
     Blast Phase (BP)  1 (5.55%) 0  
     Cytogenetic Failure   1 (5.55%) 1 (7.69%)  
     Molecular Failure  10 (55.55%) 4 (30.76%) 3 (23.07%) 
     Complete Hematologic response (CHR) 1 (5.55%) 5 (38.46%) 4 (30.76%) 
     Major Molecular Response (MMR)   1 (7.69%) 
     Early Molecular Response (EMR) 1 (5.55%)   
     Time on Months 47.5, (R 1-159) 9, (R 4.8-35.36) 24, (R 7.25-91.13)   11.6, (R 4.06-5.76) 
Best Response     
     CHR  18 (100%)  12 (92.30%) 
     Optimal  12/26 (46.15%) 7/15 (46.66%) 2 (15.38%) 8 (61.53%) 
     Warning 4 /26(15.38%) 7/15 (46.66%) 1 (7.69%) 2 (23.07%) 
     Failed 10/26 (38.46%) 1/15 (5.33%) 10 (76.92%) 2 (15.38%) 
     NA 5 (16.12%) 3/18 (16.66%)   
Latest Response     
     CHR 7 (22.58%) 16 (88.88%)  12 (92.30%) 
     Molecular Test done in patients 15 (83.33%)  13 (100%) 
     Deep Molecular 
Response 
 2 (13.33%)  3 (15.38%) 
     MMR  2 (13.33%)  4 (30.76%) 
     Early 
MolecularResponse (EMR) 
1 (3.22%) 2 (13.33%)  1 (7.7%) 
     Warning  3 (20%)  1 (7.7%) 
     Failed 29 (93.54%) 6 (40%) 13 (100%) 5 (38.46%) 
     NA  3 (16.66%)  0 
Reason for discontinuation/starting  
     Intolerance 4 (12.90%) 3 (16.66%) 1 (7.69%) 1 (7.69%) 
     Resistance 27 (87.09%) 15 (83.33%) 13 (100%) 13 (100%) 
IRMA test done in 27 (87.09%) 14 (77.77%)  13 (100%) 
     Mutation seen 15 (55.55%)   5 (35.71%)  11 (84.61%) 
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Dasatinib as a second line TKI: Eighteen 
patients received dasatinib as the second line 
therapy, median time 9 month (Range 4.8-
35.36). At baseline 15 (83.33%) patients were 
resistant to imatinib. Rest three (16.66%) who 
had had intolerance to imatinib; one 
pulmonary stenosis suffered chest discomfort, 
another patient who had rheumatic heart 
disease developed pulmonary edema and yet 
another patient had sweet syndromes along 
with resistance to imatinib. The IRMA test of 
the patient with sweet syndrome showed 
L248V mutation. She did not achieve optimal 
response with dasatinib but she maintained 
CHR.  The patient with pulmonary stenosis 
and rheumatic heart disease had optimal 
response as early molecular response (EMR) 
and complete hematologic response (CHR). 
Both of these patients achieved the deep 
molecular response (MR4) and major 
molecular response (MMR) respectively with 
dasatinib, (Table 3).  
 
In 15 patients, five had hematologic failure, 
nine had molecular failure and one had 
cytogenetic failure. Altogether 14 (77.77%) 
patients underwent mutational analysis using 
IRMA. Mutations were observed in 5 
(35.71%%) patients and not seen in 9 
(64.28%). In four, it was not performed. CHR 
was achieved as the best response on those 
patients in whom mutation was seen.  
Reports of molecular test was available in 15 
patients and in three it was not. Seven 
(46.66%) patients achieved the optimal 
response as the best response. Warning 
response was seen in seven (46.66%) patients 
as the best response. In one (6.66%) patient 
there was failed response. All three patients 
without molecular tests, they were able to 
achieve CHR. 
 
After dasatinib was used as second line, in 
total 16 (88.88%) patients were able to 
achieve CHR, and two (11.11%) patients 
progressed to hematologic resistance. Deep 
molecular response was achieved by two 
(13.33%) patients, major molecular response 
by two (13.33%), early molecular response by 
two (13.33%), warning by three (20%) and the 
resistance was observed in six (40%) patients.  
 
 
Table 3. Showing the mutation status and response with second and third line dasatinib 
 
 
Dasatinib as a Second line TKI 
SN Mutation  Number Failed HR CHR 
QPCR MR4 MMR EMR Warn Fail 
1 Y253H 1 none 1 done   1    2 G250E 1 AP 1 not done      
3 L248V 1 none 1  done     1 4 A269S 1 none 1 done      1 5 M244V 1 none 0 done      1 6 not seen 9 4 8  1 0 2 3 2 
7 Not done 4 none 4 3 1 1   1 Dasatinib as a Third line TKI 
1 H396R 1 AP 1 done     1 2 Y253H 2 CP 1 2 2 1    1 3 F359V/C*# 5 CP2+AP2 5 5 0 3  1 1 4 L387M^ 1 CP 1 done 1     5 E255K/V^& 2 CP1 2 done 1  1   6 E355G^ 1 CP 1 done 1     7 M351T& 1 none 1 done   1   8 E275K* 1 CP 1 done  1    9 M244V# 1 CP 1 done  1    10 F317L 1 AP 0 done     1 11 not seen 2 CP1 2 done  1   1 
Note: HR: Hematological Response, CHR: Complete Haematological Response, QPCR: Quantitative Polymerase 
Chain Reaction, MR4: Deep Molecular Response, MMR: Major Molecular Response, EMR: Early Molecular 
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In three patients the molecular tests were not 
available but complete hematologic response 
was achieved. Thus, 26.66% of the patients 
were able to achieve at least an MMR. In the 
patients who had mutation, one patient was 
able to achieve MMR. The dasatinib sensitive 
mutation like Y253H, G250E and M244V were 
seen in three patients. One (M244V) (5.55%) 
had primary resistance and succumbed due to 
disease progression. IRMA analysis did not 




Figure 1. Figure showing the event free survival curve, where death, failure and lost to follow up were taken 
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In four patients IRMA was not performed. 
One was able to achieve deep molecular 
response, one MMR and one had primary 
resistance to dasatinib. In the remaining one 
patient, the molecular tests were not 
performed but CHR was achieved. The event 
free survival was 70% at 10 months The 
median event free survival was 14 months. 
Overall survival was 92% at 20 months. 
 
Dasatinib as a third line TKI: Dasatinib was 
used as a third line TKI in 13 patients median 
time 11.16 months, (Range 4.06-35.766 
months). These patients received nilotinib 
after failing (12) or not tolerating (1) imatinib. 
The median duration on nilotinib was 24 
months (R 7.25-91.13).  One patient was 
switched to nilotinib as he had acute kidney 
injury following imatinib therapy. However, 
he needed to be changed to dasatinib as his 
kidney injury worsened with nilotinib too and 
he also had a prolonged QTc interval. He 
achieved the optimal responses as the best 
response with all three TKIs.  
 
At base line, out of thirteen, nine (69.23%) 
patients had hematologic failure, 5 (55.55%) 
patients were in the chronic phase and 4 
(44.44%) in the accelerated phase.  Rest three 
(23.07%) patients had molecular failure but 
had maintained the complete hematologic 
response, and the last one (7.69%) patient 
had MMR. 
 
All the patients underwent mutational study 
and mutation was seen in 11 (84.61%) and in 
2 patients (15.38%) mutation was not 
detected.  
Seven patients underwent IRMA test while on 
nilotinib. New mutation was seen in three 
patients, three had the same mutation as 
before and in one patient it was not present. 
The best response as optimal response was 
achieved in 8 (61.53%), warning in 3(23.07%) 
and failed response in two (15.38%).  
 
After using dasatinib as third line complete 
hematologic response was achieved in 12 
(92.30%), deep molecular response was 
achieved in 2(15.38%), major molecular 
response in 4 (30.76%), early molecular 
response in 1 (7.7%), warning response in 1 
(7.7%) and resistance was seen in 5 (38.46%) 
patients. Thus, a minimum of MMR was 
achieved in six (46.15%) of the patients. The 
commonest mutation was F359V/C (5/11), 
Out of these five patients, three patients 
(60%) achieving at least an MMR, one patient 
achieved EMR and another one patient 
developed resistance to dasatinib 
 
In three patients, each one with H396R, 
Y253H and F359V mutations were associated 
with the primary resistance to dasatinib. 
Mutations Y253H, F359V, F359C, L387M, and 
M351T mutations were associated with good 
outcome, as all of them were associated with 
the optimal response. Out of seven patient 
having these mutations, two patients 
achieved deep molecular response, 3 
achieving a major molecular response and 
one achieving an early molecular response. 
One patient however developed the warning 
response.  
 
In two patients, the IRMA test did not show 
any mutation. Dasatinib as a third line TKI 
conferred MMR in one patient and in another 
there was a primary resistance. 
 
In a patient who never achieved the optimal 
response with imatinib had E275K mutation. 
He was started on nilotinib wherein he had a 
hematologic failure with the rise in the pcr 
value and IRMA showed F359V mutation. He 
was thus put on dasatinib. 
 
The patient who had primary resistances to 
imatinib and nilotinib had F359V mutation 
was started on dasatinib to which there was a 
good response initially but later developed a 
resistance. IRMA showed M244V mutation. 
He responded well to the dose escalation of 
dasatinib. 
 
Overall, the event free survival was 70% at 10 
months of starting dasatinib in this groups as 
shown in figure 1. The median event free 
survival was 22 months.   The overall survival 
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In our study, best hematologic response as 
CHR was achieved in 100% and 92.30% with 
2nd line and third line dasatinib respectively. It 
was maintained at 88.88% and 92.30% at the 
end of the study. In the study where dasatinib 
was used as the 2nd and 3rd line TKI, CHR was 
achieved in 28.57% and 70.58% respectively.3 
In the START C and START A trial where 
dasatinib was used in the CP and BP of CML 
CHR was achieved in 91% and 45% 
respectively.7,8 Yet in another study by Brave 
et al. on dasatinib as a second line TKI, CHR 
was seen in 90%, 33% and 24% in CP, AP and 
BP respectively. It is evident that the patients 
who are at greater phase of CML had worse 
hematologic prognosis.9 CHR achieved in 
these studies is comparable our study where 
all phases of CML were taken as a unit. 
 
In our study we did not perform cytogenetic 
study but did the molecular test. Achievement 
of MMR is better than to achieving CCyR. 
Kantarjian, et al, in their study had shown that 
the patients who had CCyR, on follow up 
showed increase in RTPCR than that of MMR 
but they maintained CCyR 10 So, in our study, 
total MMR or higher response was achieved 
in 35.71% of patients who were on dasatinib. 
MMR was achieved in 26.66% and 46.15% of 
patients receiving 2nd line and 3rd line 
dasatinib respectively. In the study performed 
in the patients on second line and third line 
TKI, over all CCyR was achieved in 64.4% of 
the patients.7 In another study the second line 
and third line dasatinib induced CCyR in 
14.28% and 26.47% respectively. In the 
START- C trial, second line dasatinib was able 
to achieve MMR in 25% of the patients where 
as in START-A  trial the second line dasatinib 
induced CCyR  in 32% of the patients.7,8 
Similarly, in the START-R trial MMR of 29% 
was achieved with second line dasatinib 
where as in another study where dasatinib is 
used as a third line TK, I MMR was achieved  
in 19.2%.11,12   Again, MMR of 11.76% was 
seen in the patients receiving third line TKI.3 
Over all the response rate is found to be 
comparable with the results of our study. In 
our study, EMR was seen in 13.33% and 7.7% 
in 2nd and 3rd line dasatinib respectively. It has 
been found that achievement of EMR to be 
associated with the improved progression 
free survival (PFS) and overall survival (OS), as 
PFS was 56% and 57% in patients EMR at 
three to six months in comparison to 21% and 
14% in those who did not achieve EMR.13 
 
Resistance to second line and third line 
dasatinib was 40% and 38.46% respectively, 
also seems to be comparable to that in the 
clinical trials. In the study on 2nd line and 3rd 
line dasatinib, resistance was seen in 
35.57%.14 In another study, the resistance to 
the 3rd line dasatinib was seen in 42%.12 In a 
study using dasatinib as a 2nd line TKI primary 
resistance was seen in 28.57% of the patients 
but 64% of the patients eventually failed.3 In 
the group using dasatinib as a third line TKI, 
primary resistance was encountered in 9%, 
and loss of CHR was seen in 18% of the 
patients and over all resistance was observed 
in 42%.3 
 
Overall mortality rate in our study was 6.45%.   
Here, using dasatinib as a second line and 
third line TKI, mortality rate was 5.55% and 
7.69% respectively.   In other studies, 
mortality rates using 3rd line dasatinib was 
37.5% and 34.6%.3,12 In the study by Brave, et 
al., the mortality rate associated with the use 
of second line dasatinib was 2%. Thus, the 
mortality rate that occurred in our study does 
not seem to be higher than that of the other 
studies. 
 
In our study, the use of both second line and 
third line dasatinib was able to achieve overall 
survival (OS) of 92% and 94% at 20 months 
respectively, and the event free survival (EFS) 
of 70% at 10 months. In the study by Garg et 
al, the event free survival was 55%, 30%, and 
18% at 13 months in patients using dasatinib 
as a 3rd line TKI in CP, AP and BP 
respectively.14 In the study by Santos, et al. 
the PFS and OS was observed in 90% at 6.7 
months and 96% at 11.8 months 
respectively.15 Similarly, in the seven year 
follow up study of dasatinib as a second line 
TKI, PFS and OS at year 2 and 7 were 70%, 
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study by Ibrahim et al, where dasatinib or 
nilotinib was used as the third line TKI,  the 30 
month OS was 72% in the patients who 
achieves CCyR and 20.4% in patients who did 
not achieve this response.12 In the START C 
and  START A trial PFS and OS was 90% and 
96% at 15 months and 66% and 82% at 12 
months respectively. 7,8 
  
In our study, the mutations in the patients, 
which were sensitive to the imatinib, nilotinib 
or dasatinib, the patients were still found not 
responding to treatment, calling into question 
the compliance to the medicines. It also 
explains the multimodal mechanisms for 
resistance, suggesting that mutation alone 
may not be the cause of the resistance to 
treatment.  
 
L387M mutation was known to be sensitive to 
all 3 TKIs but our patient had this mutation 
when he had resistance to imatinib. He later 
developed resistance to nilotinib too and 
IRMA showed the new mutations E255K and 
E355G with the absence of the previous 
L387M mutation. As E255K mutation has the 
intermediate resistance to both dasatinib and 
nilotinib and E355G mutation was sensitive to 
dasatinib. Hence, dasatinib was started here. 
 
Mutation with M351T was known to be 
sensitive to all 3 TKIs, but it was detected 
when our patient had a cytogenetic failure as 
well as a hematologic failure. This patient 
never had an optimal response to nilotinib but 
had always maintained a CHR and later 
showed molecular failure. A second new 
mutation E255V was seen which had an 
intermediate resistance to nilotinib and 
dasatinib. 
 
Limitations of our study were small sample 
size, not enough to obtain their significance 
and all phases of CML were categorized as 
one. As discovered in the clinical trials 
response rates are lower for the patients in 
the blast phase or accelerated phase than in 
the chronic phase CML. We saw that our 
patients who were supposed to have a drug 
sensitive mutation had a resistance to the 
given TKI.  In the ideal situation these patients 
would undergo assessment of plasma 
concentration of the drug to measure the 
drug compliance. This was not possible in our 
patients because the availability, validity and 




In conclusion, dasatinib is effective in 
achieving response rates like CHR, MMR, EFS, 
and OS similar to those in the clinical trials in 
the patients who are resistant to or intolerant 
to imatinib alone or following sequential 
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